Impact of pathogen-reduction technologies on COVID-19 convalescent plasma potency

被引：14

作者：

Focosi, D. ^{[1
]}

Franchini, M. ^{[2
]}

机构：

[1] Pisa Univ Hosp, North Western Tuscany Blood Bank, Via Paradisa 2, I-56124 Pisa, Italy

[2] Carlo Poma Hosp, Dept Hematol & Transfus Med, Mantua, Italy

来源：

TRANSFUSION CLINIQUE ET BIOLOGIQUE | 2021年 / 28卷 / 02期

关键词：

Pathogen inactivation; Pathogen reduction technologies; COVID-19 convalescent plasma; Neutralizing antibodies; Efficacy; IgG subclasses; FRESH-FROZEN PLASMA; ULTRAVIOLET-LIGHT; AMOTOSALEN; RIBOFLAVIN; INACTIVATION;

D O I：

10.1016/j.tracli.2021.02.005

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Pathogen reduction technologies (PRT) have been recommended by many regulatory authorities to minimize the residual risk of transfusion-transmitted infections associated with COVID19 convalescent plasma. While its impact on safety and its cost-effectiveness are nowadays well proven, there is theoretical concern that PRT could impact efficacy of convalescent plasma by altering concentration and/or function of the neutralizing antibodies (nAb). We review here the evidence supporting a lack of significant detrimental effect from PRTs on nAbs. (C) 2021 Societe francaise de transfusion sanguine (SFTS). Published by Elsevier Masson SAS. All rights reserved.

引用

页码：132 / 134

页数：3

共 50 条

[41] Challenges of Convalescent Plasma Therapy on COVID-19
Zhao, Qian
He, Yong
[J]. JOURNAL OF CLINICAL VIROLOGY, 2020, 127
[42] Late Treatment for COVID-19 With Convalescent Plasma
Senefeld, Jonathon W.
Paneth, Nigel S.
Carter, Rickey E.
Wright, R. Scott
Fairweather, DeLisa
Bruno, Katelyn A.
Joyner, Michael J.
[J]. CHEST, 2022, 162 (05) : E283 - E284
[43] Covid-19 patients treated with convalescent plasma
Nissen-Meyer, Lise Sofie Haug
Macpherson, Magnhild Eide
Skeie, Linda Gail
Hvalryg, Marte
Llohn, Abid Hussain
Steinsvag, Tine Torsvik
Fenstad, Mona Hoysaeter
Tveita, Anders
Kristoffersen, Einar K.
Sundic, Tatjana
Lund-Johansen, Fridtjof
Vaage, John Torgils
Flesland, Oystein
Dyrhol-Riise, Anne Ma
Holter, Jan Cato
Hervig, Tor Audun
Fevang, Borre
[J]. TIDSSKRIFT FOR DEN NORSKE LAEGEFORENING, 2023, 143 (11) : 958 - 962
[44] COVID-19: Convalescent plasma as a potential therapy
van den Berg, Karin
Vermeulen, Marion
Glatt, Tanya Nadia
Wasserman, Sean
Barrett, Claire L.
Peter, Jonny
Brittain, David
Louw, Vernon J.
[J]. SAMJ SOUTH AFRICAN MEDICAL JOURNAL, 2020, 110 (07): : 562 - 563
[45] Convalescent plasma in patients hospitalised with COVID-19
Liu, Sean T. H.
Aberg, Judith A.
[J]. LANCET, 2021, 397 (10289): : 2024 - 2025
[46] Convalescent plasma for COVID-19: Promising, not proven
Mucha, Simon R.
Quraishy, NurJehan
[J]. CLEVELAND CLINIC JOURNAL OF MEDICINE, 2020, 87 (11) : 664 - 670
[47] Convalescent plasma for COVID-19: Back to the future
Roberts, David J.
Miflin, Gail
Estcourt, Lise
[J]. TRANSFUSION MEDICINE, 2020, 30 (03) : 174 - 176
[48] Donating convalescent plasma for COVID-19 patients
Black, Emily
[J]. BRITISH DENTAL JOURNAL, 2020, 229 (10) : 643 - 643
[49] Convalescent Plasma for Outpatients with Covid-19 REPLY
Barry, Peter J.
Mall, Marcus A.
Polineni, Deepika
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (23): : 2208 - 2208
[50] COVID-19, Hypercoagulability, and Cautiousness with Convalescent Plasma
Sanfilippo, Filippo
La Rosa, Valeria
Oliveri, Francesco
Astuto, Marinella
[J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (02) : 257 - 258

← 1 2 3 4 5 →